



(51) International Patent Classification:

A61K 47/68 (2017.01) A61P 35/00 (2006.01)
C07K 16/30 (2006.01)

(21) International Application Number:

PCT/US2025/011010

(22) International Filing Date:

10 January 2025 (10.01.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

202410042571.5 11 January 2024 (11.01.2024) CN
202510016135.5 07 January 2025 (07.01.2025) CN

(71) Applicant: SYSTIMMUNE, INC. [US/US]; 15318 NE 95th St, Redmond, Washington 98052 (US).

(72) Inventors: ZHU, Yi; 15318 NE 95th St, Redmond, Washington 98052 (US). WAN, Weili; 139 Baili Road, Wenjiang District, Chengdu, Sichuan 611130 (CN). ZHUO, Shi; 139 Baili Road, Wenjiang District, Chengdu, Sichuan 611130 (CN). LAI, Weirong; 139 Baili Road, Wenjiang District, Chengdu, Sichuan 611130 (CN). ZHANG, Yong; 139 Baili Road, Wenjiang District, Chengdu, Sichuan 611130 (CN).

(74) Agent: WAN, Feng; EpiMED LLC, 10398 NE 17th St. Unit 306, Bellevue, Washington 98004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ANTIBODY-AURISTATIN DRUG CONJUGATES AND METHODS OF MAKING AND USING THEREOF




Figure 10

(57) Abstract: The application provides antibody-drug conjugates (ADCs) comprising an antibody moiety having a binding affinity to HER2 and a drug moiety derived from auristatin, and methods of making and using such ADCs for treating cancer. The disclosure further provides linker-drug compounds comprising auristatin derivatives, and methods of making and using thereof.

[Continued on next page]

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))